Short Interest in Revelation Biosciences, Inc. (NASDAQ:REVB) Rises By 27.0%

Revelation Biosciences, Inc. (NASDAQ:REVB) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totaling 266,200 shares, agrowthof27.0% from the July 15th total of 209,600 shares. Approximately17.4% of the company’s shares are short sold. Based on an average daily volume of 433,600 shares, the short-interest ratio is presently 0.6 days. Based on an average daily volume of 433,600 shares, the short-interest ratio is presently 0.6 days. Approximately17.4% of the company’s shares are short sold.

Revelation Biosciences Stock Performance

REVB stock opened at $2.54 on Friday. The company’s 50 day moving average price is $2.58 and its 200 day moving average price is $6.74. Revelation Biosciences has a fifty-two week low of $2.11 and a fifty-two week high of $72.96. The firm has a market capitalization of $4.32 million, a price-to-earnings ratio of -0.04 and a beta of -0.06.

Revelation Biosciences (NASDAQ:REVB) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($7.01) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($4.46) by ($2.55). Equities analysts forecast that Revelation Biosciences will post -49.33 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Revelation Biosciences to a “sell” rating in a research note on Friday, June 27th.

Revelation Biosciences Company Profile

Revelation Biosciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immune system therapeutics and diagnostics. It engages in developing therapeutic product candidates, including GEM-SSI, a potential therapy for the prevention and treatment of surgical sit infection; GEM-AKI, a potential therapy for the prevention and treatment of acute kidney injury; and GEM-CKD, a potential therapy for the prevention and treatment of chronic kidney disease.